Northwest Biotherapeutics Stock Current Liabilities
| NWBO Stock | USD 0.29 0.01 3.33% |
Northwest Biotherapeutics fundamentals help investors to digest information that contributes to Northwest Biotherapeutics' financial success or failures. It also enables traders to predict the movement of Northwest OTC Stock. The fundamental analysis module provides a way to measure Northwest Biotherapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Northwest Biotherapeutics otc stock.
Northwest |
Northwest Biotherapeutics OTC Stock Current Liabilities Analysis
Northwest Biotherapeutics' Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current Northwest Biotherapeutics Current Liabilities | 64.93 M |
Most of Northwest Biotherapeutics' fundamental indicators, such as Current Liabilities, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Northwest Biotherapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
In accordance with the recently published financial statements, Northwest Biotherapeutics has a Current Liabilities of 64.93 M. This is 96.29% lower than that of the Biotechnology sector and 88.04% lower than that of the Health Care industry. The current liabilities for all United States stocks is 99.18% higher than that of the company.
Northwest Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Northwest Biotherapeutics' direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Northwest Biotherapeutics could also be used in its relative valuation, which is a method of valuing Northwest Biotherapeutics by comparing valuation metrics of similar companies.Northwest Biotherapeutics is currently under evaluation in current liabilities category among its peers.
Northwest Fundamentals
| Return On Asset | -1.26 | ||||
| Profit Margin | 52.10 % | ||||
| Operating Margin | (54.95) % | ||||
| Current Valuation | 1.03 B | ||||
| Shares Outstanding | 1.05 B | ||||
| Shares Owned By Insiders | 10.04 % | ||||
| Shares Owned By Institutions | 0.23 % | ||||
| Number Of Shares Shorted | 14.14 M | ||||
| Price To Earning | 58.17 X | ||||
| Price To Sales | 858.96 X | ||||
| Revenue | 1 M | ||||
| Gross Profit | 1 M | ||||
| EBITDA | 184.72 M | ||||
| Net Income | 179.13 M | ||||
| Cash And Equivalents | 9.43 M | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 25.16 M | ||||
| Debt To Equity | (16.14) % | ||||
| Current Ratio | 0.10 X | ||||
| Book Value Per Share | (0.10) X | ||||
| Cash Flow From Operations | (38.3 M) | ||||
| Short Ratio | 13.54 X | ||||
| Earnings Per Share | (0.06) X | ||||
| Target Price | 5.0 | ||||
| Number Of Employees | 19 | ||||
| Beta | -0.0115 | ||||
| Market Capitalization | 705.3 M | ||||
| Total Asset | 40.16 M | ||||
| Retained Earnings | (862.01 M) | ||||
| Working Capital | (40.83 M) | ||||
| Current Asset | 24.1 M | ||||
| Current Liabilities | 64.93 M | ||||
| Z Score | -0.6 | ||||
| Net Asset | 40.16 M |
About Northwest Biotherapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Northwest Biotherapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Northwest Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Northwest Biotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Northwest Biotherapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Northwest Biotherapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Northwest Biotherapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Northwest OTC Stock
| 0.77 | DRUG | Bright Minds Biosciences | PairCorr |
| 0.61 | SABSW | SAB Biotherapeutics | PairCorr |
| 0.56 | VANI | Vivani Medical | PairCorr |
| 0.41 | VCYT | Veracyte | PairCorr |
| 0.38 | VCEL | Vericel Corp Ord | PairCorr |
The ability to find closely correlated positions to Northwest Biotherapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Northwest Biotherapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Northwest Biotherapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Northwest Biotherapeutics to buy it.
The correlation of Northwest Biotherapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Northwest Biotherapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Northwest Biotherapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Northwest Biotherapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Northwest OTC Stock
Northwest Biotherapeutics financial ratios help investors to determine whether Northwest OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Northwest with respect to the benefits of owning Northwest Biotherapeutics security.